New Drug Monitoring Assay | Vedolizumab (Entyvio®) (mAb-based) ELISA

Posted by Brandon Savela on Jun 23rd 2017

We are pleased to introduce our latest addition to our Drug Monitoring Assay Line - Vedolizumab (Entyvio®) (mAb-based) ELISA!

The drug Vedolizumab (trade name Entyvio®) is a humanized immunoglobulin G1 monoclonal antibody that binds exclusively to the lymphocyte integrin α4β7. Identification of biomarkers might be beneficial for (non-) response and risk factors for adverse drug reactions that might be related to serum drug levels and maintaining the effective concentration in order to potentially avoid some side effects with a reliable method. The specificity of this testsystem is achieved by using a monoclonal antibody named "IG-19F3" for the coating of the microtiter plate. This antibody is specific for Vedolizumab only and does not cross react with other lymphocyte integrin α4β7 catchers.

Enzyme immunoassay for the specific determination of free Vedolizumab in serum and plasma. For research use only - not for use in diagnostic procedures.

Catalog Number	IG-AB116
Species	Human
Design	Enzyme immunoassay (ELISA) technique.
Standards	5 standards, ready to use.
Controls	None provided.
Sample Types	Serum and plasma.
Sample Volume	10 µL
Assay Desc.	1 hour incubation (RT) + 30 min. (RT) + 20 min. (RT) = 1 hour, 50 min. total incubation time.
Standard Range	0 / 6 - 200 ng/mL
Sensitivity	5 ng/mL